The global APOL1 mediated kidney disease market is expected to attain a valuation of USD 3779.9 million in 2023 and is projected to reach USD 5753.9 million by 2033, trailing a CAGR of 4.3% during the forecast period.
The market is anticipated to experience growth during the projected timeframe, primarily due to significant factors such as the escalating burden of focal segmental glomerulosclerosis (FSGS) and a strong emphasis on the development of innovative treatment alternatives.
In an October 2022 article by MedSpace, it was revealed that Focal segmental glomerulosclerosis (FSGS) ranks among the most prevalent causes of primary glomerular disease in adults. When adults undergo kidney biopsy to evaluate proteinuria, approximately 35% of cases are attributed to FSGS. Moreover, African-American patients make up 80% of the subjects affected by this condition.
In a July 2022 publication by the National Library of Medicine, it was reported that focal segmental glomerulosclerosis (FSGS) is a commonly observed contributor to nephrotic syndrome, responsible for 40% of cases in adults and 20% in children. This escalating prevalence of FSGS is projected to propel the growth of the studied market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 3779.9 million |
| Anticipated Forecast Value (2033) | US$ 5753.9 million |
| Projected Growth Rate (2023 to 2033) | CAGR 4.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The APOL1 mediated kidney disease market was worth USD 3002.7 million in 2017. It accumulated a market value of USD 3627.7 million in 2022 while growing at a CAGR of 3.9% during the historical period.
According to several influential experts in the field, the APOL1 mediated kidney disease market shows significant promise, but its future path hinges entirely on the widespread availability and accessibility of APOL1 screening, particularly among young adults. While raising awareness about APOL1 genetic variants and their associated diseases is crucial, it is only the initial step toward achieving effective therapies in this domain.
By arranging free APOL1 screening initiatives, pharmaceutical companies can gather authentic data regarding the true prevalence and risk of APOL1 mediated kidney disease. These companies are projected to concentrate their efforts on populations at higher risk for APOL1 kidney diseases, particularly individuals of African descent. This targeted approach aims to streamline the screening and treatment process, saving valuable time.
Collaborative efforts between governments, pharmaceutical companies, and research institutes are being undertaken to promote awareness campaigns. Facilitating easy access to APOL1 diagnostics will create broader opportunities for pharmaceutical players. Once the product is launched, the clinical pipeline potential is expected to be significant in terms of value.
At present, the clinical pipeline for APOL1 mediated kidney disease treatment is limited, with only two pharmaceutical companies actively involved in this area. Vertex Pharmaceuticals Incorporated has its small molecule inhibitor, VX-147, in Phase 2 of clinical trials, while AstraZeneca collaborates with Ionis Pharmaceuticals for APOL1-associated chronic kidney disease, with an investigational molecule currently in Phase 1. The scarcity of treatments in the pipeline creates appealing prospects for further research and development within the market.
The market is projected to be worth USD 5753.9 million by the end of forecast period while exhibiting a CAGR of 4.3%.
Development of Next-gen Targeted Therapies to Propel Market Growth
Prominent biopharmaceutical developers in the clinical stage are directing their efforts toward developing next-generation targeted therapeutics to combat APOL1 mediated kidney diseases, particularly chronic kidney diseases. The potential for addressing unmet needs in this field is attracting both established and emerging biopharmaceutical companies to pursue a targeted therapeutic approach. This emerging trend is anticipated to provide a competitive edge and establish exclusive market dominance on a global scale in the coming years.
The global market for chronic kidney disease drugs is expected to experience substantial growth, driven by the rising number of drug approvals from regulatory authorities. A notable instance of this is the recent announcement by Bayer AG, a pharmaceutical company, on June 30, 2022.
The Chinese National Medical Products Administration (NMPA) granted marketing authorization for Finerenone, which is marketed under the name Kerendia. Kerendia, available in 10 mg or 20 mg dosages, is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist specifically indicated for the treatment of chronic kidney disease (CKD). This regulatory approval exemplifies the positive momentum in the market's expansion.
Principal Consultant
High Cost of Treatment may Restrain Market Expansion
Market growth may face hindrances due to the high cost of dialysis and kidney transplants. Also, the side effects associated with these medications such as loss of appetite, fever, and rashes are expected to hold back market expansion.
North America Driving Growth with Significant CAGR
The North American APOL1 mediated kidney disease market accounted for a revenue share of 85.4% in 2022. The demand outlook for APOL1 mediated kidney disease treatment in the region is expected to grow with a CAGR of 4.1% during the forecast period.
In 2020, the United States market value for symptomatic treatment exceeded US$ 2.0 billion and is projected to experience remarkable growth momentum. APOL1 associated kidney diseases are notably prevalent among black Americans, as these mutations have been shown to be inherited within populations of African origin.
According to the United States Census, approximately 13% of the United States population comprises African Americans. Among populations of African origin, the prevalence of APOL1-associated kidney diseases is the highest compared to other regions. Additionally, the prevalence rate of hypertension-attributable kidney disease is 12% among this demographic. Furthermore, the current therapeutic pipeline is primarily focused on launching in the regional market. These factors collectively establish the United States as a prominent player in the APOL1-mediated kidney disease treatment market.
Asia Pacific Driving Growth with a Significant CAGR
The market in Asia Pacific is expected to grow with a significant CAGR of 4.2% during the forecast period. India is expected to dominate the Asia Pacific market and is expected to grow with a CAGR of 4.4% throughout the forecast period.
The growth of the market can be attributed to the rising prevalence of end-stage diseases and significant investments in healthcare by governments in the Asia-Pacific region. Additionally, the APOL 1 mediated kidney disease treatment market in India is expected to hold a leading market share, while the market in China is projected to be a rapidly growing market in the Asia-Pacific region.
India's healthcare sector is experiencing a significant growth rate, and the prevalence of chronic kidney disease is also on the rise due to factors such as increased life expectancy and a sedentary lifestyle. This is expected to drive growth in the chronic kidney disease market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Chronic Kidney Disease to Drive Growth with Significant CAGR
In 2022, the chronic kidney disease segment accounted for a colossal revenue share of 95.07% in the APOL 1 mediated kidney disease therapeutics market. The segment is expected to flourish at a significant CAGR of 5.8% during the forecast period.
Funding allocated for kidney research falls short compared to oncology research, despite the number of individuals diagnosed with kidney disorders each year surpassing those diagnosed with cancer. This disparity is evident in the significant focus on new drug discoveries in the field of oncology, while nephrology research lags behind. By the second quarter of 2019, there was only one late-stage study dedicated to nephrology, while 39 studies were conducted in the field of cancer.
The National Institutes of Health (NIH) allocated funding for cancer research that was ten times greater than the funding for kidney disorders. It is reported that approximately 20 percent of individuals over the age of 60 have chronic kidney disease (CKD). Surprisingly, the pipelines of ten prominent pharmaceutical companies contain fewer than 30 active molecules dedicated to nephrology, whereas the number reaches 1,300 for cancer.
According to the American Society of Nephrology (ASN) Research Advocacy Committee, NIH spending for cancer patients exceeds $500 per year, while for chronic kidney disease patients it is only $30. The limited activity in kidney research has significantly impacted the healthcare industry. Several expensive phase III trials in kidney research have failed to achieve improved outcomes, further diminishing interest in the field.
The end-stage renal segment is expected to grow with a CAGR of 2.1% during the forecast period. The growth is attributed to is expected to factors such as a growing number of kidney failure patients and the introduction of advanced products like low-maintenance dialysis equipment and artificial kidneys.
The increasing number of patients, with a 5-7% annual increase, requiring kidney transplants or dialysis for survival is shaping the segment growth. Additionally, the rising incidence of renal failure in developed and developing countries has stimulated the introduction of technologically advanced products in the market.
Start-ups play a crucial role in identifying growth opportunities in various markets, including the APOL1 mediated kidney disease market. Their ability to generate high returns contributes to the expansion of the industry. Start-ups are often more efficient in converting inputs into outputs and are adaptable to unpredictable market conditions. Here are some start-ups expected to drive growth in the APOL1 mediated kidney disease treatment market.
The APOL1 mediated kidney disease market is extremely competitive and consists of various key industry players. These players are heavily investing in manufacturing APOL1 mediated kidney disease.
The key industry players are Vertex Pharmaceuticals Incorporated, Ionis Pharmaceuticals, AstraZeneca, Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Roche Holding AG.
Some recent developments in the market are:
Key industry players leverage organic growth strategies like acquisition, mergers, partnerships, and collaboration to enhance their product portfolio. This is expected to fuel the global APOL1 mediated kidney disease market.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 3779.9 million |
| Market Value in 2033 | US$ 5753.9 million |
| Growth Rate | CAGR of 4.3% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market is valued at US$ 3.7 billion in 2023.
Vertex Pharmaceuticals Incorporated, and Ionis Pharmaceuticals are key market players.
The market shall reach US$ 5.7 billion in 2033.
The market is forecast to register a CAGR of 4.3% through 2033.
From 2017 to 2022, the market registered a CAGR of 3.9%.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
5.3.1. Chronic Kidney Disease
5.3.1.1. Focal segmental glomerulosclerosis (FSGS)
5.3.1.2. Human immunodeficiency virus (HIV)-associated Nephropathy
5.3.1.3. Hypertension-associated Kidney Disease
5.3.2. End-Stage Kidney Disease
5.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
6.1. Introduction
6.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
6.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa
6.4. Market Attractiveness Analysis By Region
7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
7.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
7.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
7.2.1. By Country
7.2.1.1. The USA
7.2.1.2. Canada
7.2.2. By Indication
7.3. Market Attractiveness Analysis
7.3.1. By Country
7.3.2. By Indication
7.4. Key Takeaways
8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. Brazil
8.2.1.2. Mexico
8.2.1.3. Rest of Latin America
8.2.2. By Indication
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Indication
8.4. Key Takeaways
9. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Germany
9.2.1.2. United Kingdom
9.2.1.3. France
9.2.1.4. Spain
9.2.1.5. Italy
9.2.1.6. Russia
9.2.1.7. Rest of Europe
9.2.2. By Indication
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Indication
9.4. Key Takeaways
10. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. China
10.2.1.2. Japan
10.2.1.3. India
10.2.1.4. South Korea
10.2.1.5. Australia
10.2.1.6. Rest of APAC
10.2.2. By Indication
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Indication
10.4. Key Takeaways
11. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. South Africa
11.2.1.2. Saudi Arabia
11.2.1.3. UAE
11.2.1.4. Israel
11.2.1.5. Rest of MEA
11.2.2. By Indication
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Indication
11.4. Key Takeaways
12. Key Countries Market Analysis
12.1. USA
12.1.1. Pricing Analysis
12.1.2. Market Share Analysis, 2022
12.1.2.1. By Indication
12.2. Canada
12.2.1. Pricing Analysis
12.2.2. Market Share Analysis, 2022
12.2.2.1. By Indication
12.3. Brazil
12.3.1. Pricing Analysis
12.3.2. Market Share Analysis, 2022
12.3.2.1. By Indication
12.4. Mexico
12.4.1. Pricing Analysis
12.4.2. Market Share Analysis, 2022
12.4.2.1. By Indication
12.5. Germany
12.5.1. Pricing Analysis
12.5.2. Market Share Analysis, 2022
12.5.2.1. By Indication
12.6. United Kingdom
12.6.1. Pricing Analysis
12.6.2. Market Share Analysis, 2022
12.6.2.1. By Indication
12.7. France
12.7.1. Pricing Analysis
12.7.2. Market Share Analysis, 2022
12.7.2.1. By Indication
12.8. Spain
12.8.1. Pricing Analysis
12.8.2. Market Share Analysis, 2022
12.8.2.1. By Indication
12.9. Italy
12.9.1. Pricing Analysis
12.9.2. Market Share Analysis, 2022
12.9.2.1. By Indication
12.10. Russia
12.10.1. Pricing Analysis
12.10.2. Market Share Analysis, 2022
12.10.2.1. By Indication
12.11. China
12.11.1. Pricing Analysis
12.11.2. Market Share Analysis, 2022
12.11.2.1. By Indication
12.12. Japan
12.12.1. Pricing Analysis
12.12.2. Market Share Analysis, 2022
12.12.2.1. By Indication
12.13. India
12.13.1. Pricing Analysis
12.13.2. Market Share Analysis, 2022
12.13.2.1. By Indication
12.14. South Korea
12.14.1. Pricing Analysis
12.14.2. Market Share Analysis, 2022
12.14.2.1. By Indication
12.15. Australia
12.15.1. Pricing Analysis
12.15.2. Market Share Analysis, 2022
12.15.2.1. By Indication
12.16. South Africa
12.16.1. Pricing Analysis
12.16.2. Market Share Analysis, 2022
12.16.2.1. By Indication
12.17. Saudi Arabia
12.17.1. Pricing Analysis
12.17.2. Market Share Analysis, 2022
12.17.2.1. By Indication
12.18. UAE
12.18.1. Pricing Analysis
12.18.2. Market Share Analysis, 2022
12.18.2.1. By Indication
12.19. Israel
12.19.1. Pricing Analysis
12.19.2. Market Share Analysis, 2022
12.19.2.1. By Indication
13. Market Structure Analysis
13.1. Competition Dashboard
13.2. Competition Benchmarking
13.3. Market Share Analysis of Top Players
13.3.1. By Regional
13.3.2. By Indication
14. Competition Analysis
14.1. Competition Deep Dive
14.1.1. Pfizer Inc.
14.1.1.1. Overview
14.1.1.2. Product Portfolio
14.1.1.3. Profitability by Market Segments
14.1.1.4. Sales Footprint
14.1.1.5. Strategy Overview
14.1.1.5.1. Marketing Strategy
14.1.2. AstraZeneca
14.1.2.1. Overview
14.1.2.2. Product Portfolio
14.1.2.3. Profitability by Market Segments
14.1.2.4. Sales Footprint
14.1.2.5. Strategy Overview
14.1.2.5.1. Marketing Strategy
14.1.3. Novartis AG
14.1.3.1. Overview
14.1.3.2. Product Portfolio
14.1.3.3. Profitability by Market Segments
14.1.3.4. Sales Footprint
14.1.3.5. Strategy Overview
14.1.3.5.1. Marketing Strategy
14.1.4. GlaxoSmithKline plc
14.1.4.1. Overview
14.1.4.2. Product Portfolio
14.1.4.3. Profitability by Market Segments
14.1.4.4. Sales Footprint
14.1.4.5. Strategy Overview
14.1.4.5.1. Marketing Strategy
14.1.5. Merck & Co., Inc.
14.1.5.1. Overview
14.1.5.2. Product Portfolio
14.1.5.3. Profitability by Market Segments
14.1.5.4. Sales Footprint
14.1.5.5. Strategy Overview
14.1.5.5.1. Marketing Strategy
14.1.6. Sanofi S.A.
14.1.6.1. Overview
14.1.6.2. Product Portfolio
14.1.6.3. Profitability by Market Segments
14.1.6.4. Sales Footprint
14.1.6.5. Strategy Overview
14.1.6.5.1. Marketing Strategy
14.1.7. Johnson & Johnson
14.1.7.1. Overview
14.1.7.2. Product Portfolio
14.1.7.3. Profitability by Market Segments
14.1.7.4. Sales Footprint
14.1.7.5. Strategy Overview
14.1.7.5.1. Marketing Strategy
14.1.8. AbbVie Inc.
14.1.8.1. Overview
14.1.8.2. Product Portfolio
14.1.8.3. Profitability by Market Segments
14.1.8.4. Sales Footprint
14.1.8.5. Strategy Overview
14.1.8.5.1. Marketing Strategy
14.1.9. Bristol-Myers Squibb Company
14.1.9.1. Overview
14.1.9.2. Product Portfolio
14.1.9.3. Profitability by Market Segments
14.1.9.4. Sales Footprint
14.1.9.5. Strategy Overview
14.1.9.5.1. Marketing Strategy
14.1.10. Roche Holding AG
14.1.10.1. Overview
14.1.10.2. Product Portfolio
14.1.10.3. Profitability by Market Segments
14.1.10.4. Sales Footprint
14.1.10.5. Strategy Overview
14.1.10.5.1. Marketing Strategy
15. Assumptions & Acronyms Used
16. Research Methodology
Explore Healthcare Insights
View Reports
APOL1 Mediated Kidney Disease Market
